Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies

In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhenling, Tu, Sanfang, Yu, Siyao, Wu, Liufang, Pan, Wanying, Chang, Ning, Zhou, Xuan, Song, Chaoyang, Li, Yuhua, He, Yanjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019219/
https://www.ncbi.nlm.nih.gov/pubmed/33416209
http://dx.doi.org/10.1111/cas.14799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019219/
https://www.ncbi.nlm.nih.gov/pubmed/33416209
http://dx.doi.org/10.1111/cas.14799

Ejemplares similares